Automation in cell and gene therapy manufacturing: from past to future

P. Moutsatsou, J. Ochs, R. H. Schmitt, C. J. Hewitt, M. P. Hanga*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

As more and more cell and gene therapies are being developed and with the increasing number of regulatory approvals being obtained, there is an emerging and pressing need for industrial translation. Process efficiency, associated cost drivers and regulatory requirements are issues that need to be addressed before industrialisation of cell and gene therapies can be established. Automation has the potential to address these issues and pave the way towards commercialisation and mass production as it has been the case for ‘classical’ production industries. This review provides an insight into how automation can help address the manufacturing issues arising from the development of large-scale manufacturing processes for modern cell and gene therapy. The existing automated technologies with applicability in cell and gene therapy manufacturing are summarized and evaluated here.

Original languageEnglish
Pages (from-to)1245-1253
Number of pages9
JournalBiotechnology Letters
Volume41
Issue number11
Early online date20 Sep 2019
DOIs
Publication statusPublished - 1 Nov 2019

Fingerprint

Gene therapy
Automation
Cell- and Tissue-Based Therapy
Genetic Therapy
Industry
Technology
Costs and Cost Analysis
Costs

Bibliographical note

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Keywords

  • Automation
  • Bioreactors
  • Cell therapy
  • Gene therapy
  • Manufacturing

Cite this

Moutsatsou, P. ; Ochs, J. ; Schmitt, R. H. ; Hewitt, C. J. ; Hanga, M. P. / Automation in cell and gene therapy manufacturing : from past to future. In: Biotechnology Letters. 2019 ; Vol. 41, No. 11. pp. 1245-1253.
@article{d4fb6683fd4e47579edb69cd58b2db02,
title = "Automation in cell and gene therapy manufacturing: from past to future",
abstract = "As more and more cell and gene therapies are being developed and with the increasing number of regulatory approvals being obtained, there is an emerging and pressing need for industrial translation. Process efficiency, associated cost drivers and regulatory requirements are issues that need to be addressed before industrialisation of cell and gene therapies can be established. Automation has the potential to address these issues and pave the way towards commercialisation and mass production as it has been the case for ‘classical’ production industries. This review provides an insight into how automation can help address the manufacturing issues arising from the development of large-scale manufacturing processes for modern cell and gene therapy. The existing automated technologies with applicability in cell and gene therapy manufacturing are summarized and evaluated here.",
keywords = "Automation, Bioreactors, Cell therapy, Gene therapy, Manufacturing",
author = "P. Moutsatsou and J. Ochs and Schmitt, {R. H.} and Hewitt, {C. J.} and Hanga, {M. P.}",
note = "{\circledC} The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",
year = "2019",
month = "11",
day = "1",
doi = "10.1007/s10529-019-02732-z",
language = "English",
volume = "41",
pages = "1245--1253",
journal = "Biotechnology Letters",
issn = "0141-5492",
publisher = "Springer",
number = "11",

}

Automation in cell and gene therapy manufacturing : from past to future. / Moutsatsou, P.; Ochs, J.; Schmitt, R. H.; Hewitt, C. J.; Hanga, M. P.

In: Biotechnology Letters, Vol. 41, No. 11, 01.11.2019, p. 1245-1253.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Automation in cell and gene therapy manufacturing

T2 - from past to future

AU - Moutsatsou, P.

AU - Ochs, J.

AU - Schmitt, R. H.

AU - Hewitt, C. J.

AU - Hanga, M. P.

N1 - © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - As more and more cell and gene therapies are being developed and with the increasing number of regulatory approvals being obtained, there is an emerging and pressing need for industrial translation. Process efficiency, associated cost drivers and regulatory requirements are issues that need to be addressed before industrialisation of cell and gene therapies can be established. Automation has the potential to address these issues and pave the way towards commercialisation and mass production as it has been the case for ‘classical’ production industries. This review provides an insight into how automation can help address the manufacturing issues arising from the development of large-scale manufacturing processes for modern cell and gene therapy. The existing automated technologies with applicability in cell and gene therapy manufacturing are summarized and evaluated here.

AB - As more and more cell and gene therapies are being developed and with the increasing number of regulatory approvals being obtained, there is an emerging and pressing need for industrial translation. Process efficiency, associated cost drivers and regulatory requirements are issues that need to be addressed before industrialisation of cell and gene therapies can be established. Automation has the potential to address these issues and pave the way towards commercialisation and mass production as it has been the case for ‘classical’ production industries. This review provides an insight into how automation can help address the manufacturing issues arising from the development of large-scale manufacturing processes for modern cell and gene therapy. The existing automated technologies with applicability in cell and gene therapy manufacturing are summarized and evaluated here.

KW - Automation

KW - Bioreactors

KW - Cell therapy

KW - Gene therapy

KW - Manufacturing

UR - http://www.scopus.com/inward/record.url?scp=85073763927&partnerID=8YFLogxK

UR - https://link.springer.com/article/10.1007%2Fs10529-019-02732-z

U2 - 10.1007/s10529-019-02732-z

DO - 10.1007/s10529-019-02732-z

M3 - Review article

C2 - 31541330

AN - SCOPUS:85073763927

VL - 41

SP - 1245

EP - 1253

JO - Biotechnology Letters

JF - Biotechnology Letters

SN - 0141-5492

IS - 11

ER -